Snapshot · Boston Scientific Corporation (BSX)

Data as of 2026-10-18T09:41:41.254Z

Fundamentals check

Market cap

$64.3B

P/E (TTM)

17.9

Gross margin

71.2%

Net margin

17.5%

ROE

14.9%

R&D / revenue

10.3%

Dividend yield

0.0%

FCF yield

5.6%

Summary

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

How it makes money

Revenue mix, latest fiscal year

• Cardiovascular66%
• MedSurg34%

Recent Events

• 2026-10-07T06:00:00.000Zneutral

  Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

  恰逢管理层变动，可能对公司治理与执行效率产生影响，存在不确定性。

  Source: prnewswire.com

• 2026-10-01T16:45:00.000Zneutral

  Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

  恰逢资金安排完成，可能与公司融资与并购相关的长期展望相关。

  Source: globenewswire.com

• 2026-09-08T06:58:00.000Znegative

  Boston Scientific Won't Meet Guidance Due to Cyberattack

  可能与网络攻击导致的业绩下滑相关，事件对 BSX 短期股价压力有影响的概率较高。

  Source: wsj.com

• 2026-09-08T00:00:00.000Znegative

  Price move: BSX fell 5.9%

  BSX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-20T00:00:00.000Znegative

  Price move: BSX fell 5.1%

  BSX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-03T00:00:00.000Zpositive

  Price move: BSX rose 3.6%

  BSX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $60.11 from 19 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-25BuyMorano Susan E(director)2,040 shares
• 2026-08-05BuyHabiger David C(director)2,100 shares
• 2026-08-04BuyHabiger David C(director)140 shares
• 2026-08-03BuyMahoney Michael F(director, officer: Chairman, President & CEO)186,240 shares
• 2026-08-03BuyHabiger David C(director)1,042 shares

US Congress trading disclosures

• 2026-06-04John Boozman (AR)Sale (Partial)$1,001 - $15,000

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。